Delayed
Japan Exchange
08:00:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
69
JPY
|
-1.43%
|
|
-1.43%
|
-13.75%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
9,942
|
12,479
|
11,001
|
6,833
|
6,245
|
4,485
|
Enterprise Value (EV)
1 |
-994.8
|
4,781
|
5,004
|
2,617
|
2,345
|
1,860
|
P/E ratio
|
-3.15
x
|
-4.04
x
|
-4.38
x
|
-2.59
x
|
-2.81
x
|
-2.99
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
29,73,14,870
x
|
-
|
78,06,80,634
x
|
11,50,00,855
x
|
EV / Revenue
|
-
|
-
|
13,52,33,789
x
|
-
|
29,31,80,634
x
|
4,76,93,163
x
|
EV / EBITDA
|
0.31
x
|
-1.47
x
|
-2
x
|
-1.01
x
|
-1.14
x
|
-1.31
x
|
EV / FCF
|
0.67
x
|
-2.1
x
|
-3.41
x
|
-1.63
x
|
-1.67
x
|
-1.88
x
|
FCF Yield
|
148%
|
-47.7%
|
-29.3%
|
-61.4%
|
-60%
|
-53.1%
|
Price to Book
|
0.95
x
|
1.55
x
|
1.85
x
|
1.65
x
|
1.59
x
|
1.69
x
|
Nbr of stocks (in thousands)
|
40,252
|
42,303
|
44,179
|
45,862
|
54,308
|
56,063
|
Reference price
2 |
247.0
|
295.0
|
249.0
|
149.0
|
115.0
|
80.00
|
Announcement Date
|
28/03/19
|
27/03/20
|
29/03/21
|
29/03/22
|
29/03/23
|
29/03/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
37
|
-
|
8
|
39
|
EBITDA
1 |
-3,252
|
-3,243
|
-2,497
|
-2,585
|
-2,053
|
-1,417
|
EBIT
1 |
-3,273
|
-3,288
|
-2,542
|
-2,644
|
-2,111
|
-1,504
|
Operating Margin
|
-
|
-
|
-6,870.27%
|
-
|
-26,387.5%
|
-3,856.41%
|
Earnings before Tax (EBT)
1 |
-3,046
|
-3,104
|
-2,437
|
-2,616
|
-2,015
|
-1,489
|
Net income
1 |
-3,046
|
-3,065
|
-2,437
|
-2,616
|
-2,015
|
-1,489
|
Net margin
|
-
|
-
|
-6,586.49%
|
-
|
-25,187.5%
|
-3,817.95%
|
EPS
2 |
-78.42
|
-73.06
|
-56.90
|
-57.46
|
-40.92
|
-26.79
|
Free Cash Flow
1 |
-1,475
|
-2,280
|
-1,468
|
-1,608
|
-1,407
|
-987.6
|
FCF margin
|
-
|
-
|
-3,966.89%
|
-
|
-17,590.62%
|
-2,532.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/03/19
|
27/03/20
|
29/03/21
|
29/03/22
|
29/03/23
|
29/03/24
|
Fiscal Period: December |
2020 S1
|
2021 S1
|
2021 Q3
|
2022 Q1
|
2022 S1
|
2022 Q3
|
2023 Q1
|
2023 S1
|
2023 Q3
|
---|
Net sales
1 |
0.3554
|
-
|
-
|
-
|
-
|
0.0144
|
0.037
|
0.1184
|
0.0924
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-12.08
|
-12.08
|
-5.027
|
-4.984
|
-8.828
|
-3.388
|
-3.288
|
-5.203
|
-1.874
|
Operating Margin
|
-3,400.03%
|
-
|
-
|
-
|
-
|
-23,580.31%
|
-8,898.94%
|
-4,394.18%
|
-2,028.52%
|
Earnings before Tax (EBT)
1 |
-11.72
|
-12.22
|
-5.088
|
-5.069
|
-9.009
|
-3.41
|
-3.281
|
-5.182
|
-1.867
|
Net income
1 |
-11.72
|
-12.23
|
-5.088
|
-5.076
|
-9.016
|
-3.41
|
-3.281
|
-5.189
|
-1.86
|
Net margin
|
-3,297.39%
|
-
|
-
|
-
|
-
|
-23,727.42%
|
-8,878.94%
|
-4,382.42%
|
-2,014.23%
|
EPS
2 |
-29.64
|
-29.86
|
-12.64
|
-14.30
|
-26.02
|
-9.180
|
-8.090
|
-13.48
|
-5.050
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/08/20
|
12/08/21
|
12/11/21
|
13/05/22
|
12/08/22
|
11/11/22
|
12/05/23
|
10/08/23
|
14/11/23
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
10,937
|
7,698
|
5,997
|
4,216
|
3,900
|
2,625
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1,475
|
-2,280
|
-1,468
|
-1,608
|
-1,407
|
-988
|
ROE (net income / shareholders' equity)
|
-25.9%
|
-32.9%
|
-34.6%
|
-51.6%
|
-49.7%
|
-45.1%
|
ROA (Net income/ Total Assets)
|
-16.6%
|
-20.5%
|
-20.6%
|
-28.7%
|
-28.5%
|
-25.3%
|
Assets
1 |
18,379
|
14,937
|
11,835
|
9,121
|
7,064
|
5,889
|
Book Value Per Share
2 |
261.0
|
191.0
|
134.0
|
90.60
|
72.30
|
47.20
|
Cash Flow per Share
2 |
64.00
|
99.10
|
56.80
|
86.70
|
74.10
|
49.40
|
Capex
1 |
22
|
-
|
13
|
8
|
57
|
66
|
Capex / Sales
|
-
|
-
|
35.14%
|
-
|
712.5%
|
169.23%
|
Announcement Date
|
28/03/19
|
27/03/20
|
29/03/21
|
29/03/22
|
29/03/23
|
29/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -13.75% | 25.04M | | +26.47% | 661B | | +26.74% | 566B | | -6.33% | 352B | | +19.35% | 332B | | +4.23% | 283B | | +13.43% | 231B | | +4.71% | 200B | | -9.53% | 195B | | -4.04% | 145B |
Other Pharmaceuticals
|